National Comprehensive Cancer Network



About NCCN

Pancreatic Adenocarcinoma Panel - Disclosures as of 5/23/2013

View NCCN Management Team Disclosures | View NCCN Guidelines Staff Disclosures | View NCCN ORP Staff Disclosures

Panel Member Clinical Research Support Advisory Boards, Speakers Bureau, Expert Witness, or Consultant Patent, Equity, or Royalty Other Date Completed

Stephen Behrman, MD

None

None

None

None

4/22/2013

Al B. Benson III, MD, FACP

Abbott Laboratories;
Amgen Inc.;
Bayer HealthCare;
Genentech, Inc.;
Alchemia;
gilead;
Infinity

Agendia BV;
Bayer HealthCare;
Daiichi- Sankyo Co.;
Eli Lilly and Company;
Genentech, Inc.;
Genomic Health, Inc.;
National Cancer Institute;
Precision Therapeutics, Inc.

None

None

8/31/2012

Ephraim S. Casper, MD

None

None

None

None

8/16/2012

E. Gabriela Chiorean, MD

Abraxis Oncology

None

None

None

7/5/2012

Vincent Chung, MD

None

None

None

None

11/9/2012

Steven J. Cohen, MD

Genentech, Inc.

Genentech, Inc.

None

None

9/17/2012

Brian Czito, MD

Abbott Laboratories;
Amgen Inc.

None

None

None

8/17/2012

Mary Feng, MD

None

None

None

None

6/15/2012

Deborah Freedman-Cass, PhD

None

None

None

None

3/7/2013

Lauren Gallagher, RPh, PhD

None

None

None

None

6/5/2012

Kristina M. Gregory, RN, MSN, OCN

None

None

None

None

10/23/2012

William G. Hawkins, MD

Adura;
Gilead;
New Link Genetics

None

None

None

9/14/2012

Joseph Herman, MD

Elekta

None

None

None

4/12/2013

John P. Hoffman, MD

None

None

None

None

4/11/2013

Andrew H. Ko, MD

AstraZeneca Pharmaceuticals LP;
Celgene Corporation;
ImClone Systems Incorporated;
Infinity Pharmaceuticals;
Merrimack/PharmaEngine;
Seattle Genetics;
Pfizer Inc.

Celgene Corporation;
Genentech, Inc.;
Clovis Pharmaceuticals

None

None

10/8/2012

Srinadh Komanduri, MD

None

None

None

None

10/9/2012

Albert Koong, MD, PhD

None

None

None

None

9/20/2012

Wen Wee Ma, MD

None

None

None

None

9/14/2012

Mokenge P. Malafa, MD, FACS

None

None

None

None

9/14/2012

Joan S. McClure, MS

None

None

None

None

7/23/2012

Nipun B. Merchant, MD

None

None

None

None

12/13/2011

Sean J. Mulvihill, MD

National Cancer Institute

None

None

None

9/14/2012

Peter Muscarella II, MD

GlobeImmune

None

None

None

9/11/2012

Eric K. Nakakura, MD

None

None

None

None

10/27/2011

Jorge Obando, MD

None

None

None

None

9/18/2012

Martha B. Pitman, MD

None

None

None

None

10/9/2012

Sushanth Reddy, MD

None

None

None

None

2/2/2013

Aaron R. Sasson, MD

None

Novartis Pharmaceuticals Corporation

None

None

10/8/2012

Dorothy Shead, MS

None

None

None

None

8/3/2012

Anitra Talley

None

None

None

None

9/19/2012

Margaret A. Tempero, MD

None

Celgene Corporation;
Myriad Genetic Laboratories, Inc.;
Onyx Pharmaceuticals, Inc.;
Antisense Pharma;
Astrellas Pharma;
Bayer Pharmaceutics;
Clovis Oncology;
Corvidien/Mallinckrodt, Inc;
Five3 Genomics;
Glycomimetics, Inc;
Halozyme Therapeutics;
Health NY/Omnicom Company;
Lilly Oncology;
Merck EMD Serono;
NPS Pharmaceutical;
OncoGenex;
Prism Biolab;
Takeda Oncology Company/Millennium;
Talon Therapeutics;
sanofi-aventis U.S.

None

None

7/11/2012

Sarah P. Thayer, MD, PhD

None

Lustgarten Foundation

None

None

9/20/2012

Robert A. Wolff, MD

None

Eli Lilly and Company

None

None

7/12/2012

Brian M. Wolpin, MD, MPH

None

None

None

None

7/11/2012

 

About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved